{"nctId":"NCT02555683","briefTitle":"Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.","startDateStruct":{"date":"2015-12-11","type":"ACTUAL"},"conditions":["Asthma"],"count":894,"armGroups":[{"label":"QAW039 150 mg","type":"EXPERIMENTAL","interventionNames":["Drug: QAW039"]},{"label":"QAW039 450 mg","type":"EXPERIMENTAL","interventionNames":["Drug: QAW039"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"QAW039","otherNames":[]},{"name":"QAW039","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Written informed consent and assent (if applicable).\n* Male and female patients aged ≥12 years (or ≥lower age limit allowed by health authority and/or ethics committee/institutional review board approvals).\n* A diagnosis of severe asthma, uncontrolled on GINA 4/5 asthma medication.\n* Evidence of airway reversibility or airway hyper- reactivity.\n* FEV1 of ≤80% of the predicted normal value for patients aged ≥18 years; FEV1 of ≤90% for patients aged 12 to \\<18 years\n* An ACQ score ≥1.5.\n* A history of 2 or more asthma exacerbations within the 12 months prior to entering the study.\n\nExclusion Criteria:\n\n* Use of other investigational drugs within 5 half-lives of study entry, or within 30 days, whichever is longer.\n* Subjects who have participated in another trial of QAW039.\n* A QTcF (Fridericia) ≥450 msec (male) or ≥460 msec (female).\n* History of malignancy with the exception of local basal cell carcinoma of the skin.\n* Pregnant or nursing (lactating) women.\n* Serious co-morbidities.\n* Patients on greater than 20 mg of simvastatin, greater than 40 mg of atorvastatin, greater than 40 mg of pravastatin, or greater than 2 mg of pitavastatin","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in High Eosinophils Subpopulation","description":"A severe asthma exacerbation is defined as treatment with 'rescue' systemic corticosteroids for greater than or equal to 3 days and hospitalization; or treatment with 'rescue' systemic corticosteroids for greater than or equal to 3 days and emergency department visit (greater than 24 hours\\*); or death due to asthma. A moderate asthma exacerbation is defined as treatment with 'rescue' systemic corticosteroids for greater than or equal to 3 days either as an outpatient or in emergency department visits (Emergency department visit less than or equal to 24 hours). The high eosinophils subpopulation consists of all patients with blood eosinophil count ≥ 250 cells/μL at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.97","spread":null},{"groupId":"OG001","value":"0.77","spread":null},{"groupId":"OG002","value":"0.93","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 52 in Asthma Quality of Life Questionnaire for Participants 12 Years and Older (AQLQ+12) Score in High Eosinophils Subpopulation","description":"The AQLQ+12 is comprised of a total of 32 individual questions that span a total of four domains: symptoms, activity limitation, emotional function, and environmental stimuli.\n\nPatients were asked to recall their experiences during the previous 2 weeks and to score each item on a 7-point scale (7 = not at all impaired to 1 = severely impaired). The AQLQ+12 yields individual domain scores, which is the mean of all items in each domain, and an overall score, which is the mean of all 32 individual responses. Higher scores indicate less impairment in health-related quality of life. The high eosinophils subpopulation consists of all patients with blood eosinophil count ≥ 250 cells/μL at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.75","spread":"0.067"},{"groupId":"OG001","value":"0.81","spread":"0.067"},{"groupId":"OG002","value":"0.68","spread":"0.067"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 52 in Asthma Control Questionnaire-5(ACQ-5) Score in High Eosinophils Subpopulation","description":"The ACQ-5 is a five-item, self-completed questionnaire, which is used as a measure of asthma control of a participant. Patients were asked to recall how their asthma had been during the previous week and to respond to the symptom questions on a 7-point scale (0=no impairment, 6=maximum impairment). The questions are equally weighted and the ACQ-5 score is the mean of the 5 questions: therefore, between 0 (totally controlled) and 6 (severely uncontrolled). The high eosinophils subpopulation consists of all patients with blood eosinophil count ≥ 250 cells/μL at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.88","spread":"0.069"},{"groupId":"OG001","value":"-0.94","spread":"0.069"},{"groupId":"OG002","value":"-0.76","spread":"0.070"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 52 in Pre-dose Forced Expiratory Volume in 1 Second (FEV1) in High Eosinophils Subpopulation","description":"Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Baseline is defined as the last available FEV1 measurement taken prior to the first dose of randomized study drug. The high eosinophils subpopulation consists of all patients with blood eosinophil count ≥ 250 cells/μL at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.169","spread":"0.0257"},{"groupId":"OG001","value":"0.153","spread":"0.0255"},{"groupId":"OG002","value":"0.103","spread":"0.0260"}]}]}]},{"type":"PRIMARY","title":"Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in Overall Population","description":"A severe asthma exacerbation is defined as treatment with 'rescue' systemic corticosteroids for greater than or equal to 3 days and hospitalization; or treatment with 'rescue' systemic corticosteroids for greater than or equal to 3 days and emergency department visit (greater than 24 hours\\*); or death due to asthma. A moderate asthma exacerbation is defined as treatment with 'rescue' systemic corticosteroids for greater than or equal to 3 days either as an outpatient or in emergency department visits (Emergency department visit less than or equal to 24 hours).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.92","spread":null},{"groupId":"OG001","value":"0.75","spread":null},{"groupId":"OG002","value":"0.96","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 52 in Asthma Quality of Life Questionnaire for Participants 12 Years and Older (AQLQ+12) Score in Overall Population","description":"The AQLQ+12 is comprised of a total of 32 individual questions that span a total of four domains: symptoms, activity limitation, emotional function, and environmental stimuli.\n\nPatients were asked to recall their experiences during the previous 2 weeks and to score each item on a 7-point scale (7 = not at all impaired to 1 = severely impaired). The AQLQ+12 yields individual domain scores, which is the mean of all items in each domain, and an overall score, which is the mean of all 32 individual responses. Higher scores indicate less impairment in health-related quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.68","spread":"0.053"},{"groupId":"OG001","value":"0.73","spread":"0.054"},{"groupId":"OG002","value":"0.61","spread":"0.054"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 52 in Asthma Control Questionnaire-5(ACQ-5) Score in Overall Population","description":"The ACQ-5 is a five-item, self-completed questionnaire, which is used as a measure of asthma control of a participant. Patients were asked to recall how their asthma had been during the previous week and to respond to the symptom questions on a 7-point scale (0=no impairment, 6=maximum impairment). The questions are equally weighted and the ACQ-5 score is the mean of the 5 questions: therefore, between 0 (totally controlled) and 6 (severely uncontrolled).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.83","spread":"0.055"},{"groupId":"OG001","value":"-0.90","spread":"0.056"},{"groupId":"OG002","value":"-0.71","spread":"0.056"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 52 in Pre-dose Forced Expiratory Volume in 1 Second (FEV1) in Overall Population","description":"Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Baseline is defined as the last available FEV1 measurement taken prior to the first dose of randomized study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.144","spread":"0.0205"},{"groupId":"OG001","value":"0.108","spread":"0.0206"},{"groupId":"OG002","value":"0.068","spread":"0.0209"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":33,"n":299},"commonTop":["Asthma","Nasopharyngitis","Upper respiratory tract infection","Viral upper respiratory tract infection","Bronchitis"]}}}